BioOva Oocyte Extract Disease treatment products have been tested in the Human & Animal models listed below and has been administered by several methods including subcutaneously, intraperitoneally, intratumorally, and topically. These studies have served to highlight broad potential across a range of tissues and administration methods, as well as to validate the universal nature of its tissue remodeling concept.

disease treatment, oocyte disease treatment, oocyte extract treatment, bioova, bioquark,

 

Key Human Treatment Results with Bioova Oocyte Extract:

Other ares of use for BioOva Oocyte extract:

Traumatic Brain Injury (TBI) –  BioOva demonstrated improvement in gross anatomical changes, reductions in B-amyloid protein expression, and improvements in hippocampus impaired spatial learning and memory.

Melanoma – BioOva demonstrated shrinkage of tumor size, prevention of new tumor formation, and reduction in tumor invasiveness biomarkers

Skin Wrinkling – BioOva demonstrated enhanced reversal of skin wrinkling

Hair Loss (Alopecia) – BioOva demonstrated re-growth of hair

Gerontological (Aging) – conducted chronic administration in both mice and fruit flies (Drosophila melanogaster) – Experimental mice lived 1.7 times longer than animals in control group and experimental Drosophila melanogaster flies lived 2.2 times longer than control group.

The longest administration of BQ-A in a disease model has been 45 days. The longest administration in a healthy animal has been for over one year. While not a formal safety study, from an observational perspective no growths, abscesses, infections, immune reactions, or behavioral changes have been seen in these animals, highlighting an intriguing and promising safety profile.